Cisplatin Clinical Trials

Cisplatin represents a heavily investigated chemotherapeutic backbone evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4. Sponsored by government institutes, cooperative groups, and academic medical centers, these studies assess treatment regimens for urothelial carcinoma, non-small cell lung cancer, head and neck cancer, neuroendocrine tumors, melanoma, and breast cancer, as well as interventions for toxicities such as hearing loss. Recruitment statuses encompass active, recruiting, and completed studies across the entire developmental continuum.

(data from https://clinicaltrials.gov, updated on 2026-07-29)

Appendix RUO and cGMP Quality Standards

Footnotes

• Cisplatin Mechanism of Action: ERCC1 Inhibition in Non-Small Cell Lung Cancer Cell Research
• Cisplatin Working Concentration | Cell Culture | Treatment
• Cisplatin Solubility in DMSO
• Cisplatin Storage
• Cisplatin Stability
• Cisplatin Combination Database
• Cisplatin Molecular Weight
• Cisplatin SMILES
• Cisplatin CAS Number
• Cisplatin Chemical Structure (2D and 3D)
• Cisplatin IC50 for Cell-based and Cell-free Assays
• Cisplatin Sigma (232120)? Try a better option.
• Cisplatin MedChemExpress (HY-17394)? Try a better option.
• Cisplatin Cayman (13119)? Try a better option.
• Cisplatin Abmole (M2223)? Try a better option.
• Cisplatin Tocris (2251)? Try a better option.
• Cisplatin SDS｜MSDS